Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]

AI-generated source summary

The analysis indicates Nuvation Bio Inc. as a Buy Candidate with a score of 3.304 as of November 3rd, 2025. It has demonstrated a gain of 39.73% over the past 11 days, averaging 3.61% daily. The stock is positioned within a robust short-term upward trend, with a potential change of approximately 74.83% over the next three months, and a 12-month forecast projecting a 24.39% change, with a price range between $2.63 and $6.70. On November 3rd, 2025, the stock closed at $5.17, experiencing a 0.96% decrease with a daily fluctuation of 5.49% and a volume of 7 million shares. Its 52-week high was $5.55, while the all-time high was $15.23 on May 26th, 2021. News includes 204 new patients receiving IBTROZI, regulatory approval in Japan, and insider trading activity showing both purchases and sales. However, general ratings indicate a Strong Sell for Return on Equity, Return on Asset, and Dividend Earnings, with a negative P/E ratio of -8.68. Technical signals show short and long-term Moving Averages giving a positive forecast, with a MACD buy signal and a Bollinger Band buy signal from 57 days ago. There is a sell signal from a pivot top found 4 days prior, indicating a 3.72% decline since. The stock exhibits very high weekly volatility at 6.70%. Key resistance is identified at $5.22, with support at $5.15. The consensus earnings estimate for Q3 2025 is -0.17. The analysis concludes with an expectation for Nuvation Bio to open higher by approximately $0.0467, trading at $5.22 on November 4th, suggesting a buying opportunity in the short-term.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   04 Nov 2025, 04:48 UTC

   The analyst published the original source item.

2. First prediction resolved

   04 Nov 2025, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   04 Nov 2025, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.